Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPV^POS Cancers.

ABSTRACT: Immunotherapy for HPV^POS malignancies is attractive because well-defined, viral, non-self tumor antigens exist as targets. Several approaches to vaccinate therapeutically against HPV E6 and E7 antigens have been adopted, including viral platforms such as VSV. A major advantage of VSV expressing these antigens is that VSV also acts as an oncolytic virus, leading to direct tumor cell killing and induction of effective anti-E6 and anti-E7 T cell responses. We have also shown that addition of immune adjuvant genes, such as IFNβ, further enhances safety and/or efficacy of VSV-based oncolytic immunovirotherapies. However, multiple designs of the viral vector are possible-with respect to levels of immunogen expression and method of virus attenuation-and optimal designs have not previou

SUBMITTER: Suksanpaisan L 

PROVIDER: S-EPMC6037044 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature